Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN53,5653,59-0,28
Msft0,35
Nokia4,1424,29958,48
IBM-0,29
Mercedes-Benz Group AG57,3557,360,70
PFE-0,17
19.10.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.10.2024
Landec Corp (LNDC.O, NASDAQ Cons)
Závěr k 18.10.2024 Změna (%) Změna (USD) Objem obchodů (ks)
5,21 2,96 0,15 176 155
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.10.2024
Popis společnosti
Obecné informace
Název společnostiLifecore Biomedical Inc
TickerLFCR
Kmenové akcie:Ordinary Shares
RICLFCR.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky26.05.2024
Poslední známé čtvrtletní výsledky25.08.2024
Počet zaměstnanců k 26.05.2024 524
Akcie v oběhu k 03.10.2024 36 827 030
MěnaUSD
Kontaktní informace
Ulice3515 Lyman Boulevard
MěstoCHASKA
PSČ55318
ZeměUnited States
Kontatní osobaStephanie Diaz
Funkce kontaktní osobyIR Contact Officer
Telefon19 523 684 300
Fax13026365454
Kontatní telefon14 156 757 401

Business Summary: Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Financial Summary: BRIEF: For the 13 weeks ended 25 August 2024, Lifecore Biomedical Inc revenues increased 1% to $24.7M. Net loss before extraordinary items increased 29% to $16.2M. Revenues reflect Revenues, related party increase of 5% to $7.9M. Higher net loss reflects single segment loss increase of 34% to $11.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.41 to -$0.53.
Odvětvová klasifikace
TRBC2009Chemicals - Specialty
TRBC2012Pharmaceuticals (NEC)
RBSS2004Chemicals - Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSFats and Oils Refining and Blending
NAICS2007Perishable Prepared Food Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007All Other Basic Inorganic Chemical Mfg
NAICS1997Perishable Prepared Food Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997All Other Basic Inorganic Chemical Manufacturing
SICPlastics Materials And Resins
SICPharmaceutical Preparations
SICEdible Fats And Oils, Nec



  • Poslední aktualizace: 20.10.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorPaul Josephs5920.05.202420.05.2024
Chief Financial Officer, Executive Vice President, Company SecretaryRyan Lake4603.09.202403.09.2024